Corbus Pharmaceuticals Holdings, Inc.
CRBP
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treaā¦ read more
Healthcare
Biotechnology
11 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$8.97
Price-0.88%
-$0.08
1Y
Price
Market Cap
$166.194m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$0.00
-
1y CAGR-
3y CAGR-25.0%
5y CAGREarnings
-$84.528m
-67.9%
1y CAGR-12.6%
3y CAGR-15.1%
5y CAGREPS
-$6.60
-49.7%
1y CAGR+4.3%
3y CAGR+5.4%
5y CAGRBook Value
$126.342m
$144.480m
Assets$18.138m
Liabilities$1.205m
DebtDebt to Assets
0.8%
-
Debt to EBITDAFree Cash Flow
-$73.654m
-42.4%
1y CAGR-18.1%
3y CAGR-8.0%
5y CAGRNo items found.
Press Releases
Statements and updates from the company